BCRX sinks 9% after competitor reports strong hereditary angioedema results
BioCryst Pharmaceuticals shares fell sharply Tuesday, dropping 9%. The selloff follows a competitor’s strong late-stage results in hereditary angioedema, the rare swelling disorder behind BioCryst’s main product.
Shares of BioCryst Pharmaceuticals (BCRX) fell sharply on Tuesday after a competitor reported strong late-stage results in hereditary angioedema, the rare swelling disorder that underpins BioCryst’s main product. BCRX fell 9% on Tuesday and posted its worst day since late February. A rival pill raised investor concern around the competitive outlook for BioCryst’s therapy.